驱动蛋白家族成员2C与卵巢癌化学药物治疗耐药的相关性

doi:10.3969/j.issn.1006-7795.2023.01.021

首都医科大学学报 ›› 2023, Vol. 44 ›› Issue (1): 143-147.doi: 10.3969/j.issn.1006-7795.2023.01.021

驱动蛋白家族成员2C与卵巢癌化学药物治疗耐药的相关性

王文文¹, 蔡昱^1*, 贾双双², 翟建军¹

1.首都医科大学附属北京同仁医院妇产科,北京 100176;
2.首都医科大学附属北京同仁医院病理科,北京 100176

收稿日期:2022-10-18 出版日期:2023-02-21 发布日期:2023-01-13
基金资助:
首都医科大学附属北京同仁医院院基金(2021YJJPY012),首都医科大学本科生科研创新项目(XSKY2022)。

Relationship between kinesin family proteins 2C and chemoresistance in ovarian cancer

Wang Wenwen¹, Cai Yu^1*, Jia Shuangshuang², Zhai Jianjun¹

1. Department of Obstetrics and Gynecology, Beijing Tongren Hospital, Capital Medical University,Beijing 100176, China;
2. Department of Pathology, Beijing Tongren Hospital, Capital Medical University,Beijing 100176, China

Received:2022-10-18 Online:2023-02-21 Published:2023-01-13
Contact: *E-mail: caiyu892002@sina.com
Supported by:
Hospital Founding of Beijing Tongren Hospital, Capital Medical University(2021YJJPY012), Undergraduate Scientific Research Innovation Project of Capital Medical University(XSKY2022).

摘要/Abstract

摘要： 目的探讨驱动蛋白家族成员2C(kinesin family proteins 2C,KIF2C)与卵巢癌化学药物治疗(以下简称化疗)耐药的相关性。方法选取2010年1月至2020年12月于首都医科大学附属北京同仁医院接受手术治疗的上皮性卵巢癌患者151例。其中铂类化疗敏感患者98例,铂类化疗耐药患者53例。利用免疫组化染色法检测KIF2C在化疗敏感及化疗耐药卵巢癌组织中的表达情况。结果卵巢癌化疗耐药组织中KIF2C明显低表达。KIF2C及病理分期ⅢC期是影响卵巢癌化疗耐药的危险因素。结论 KIF2C有可能成为预测卵巢癌患者化疗敏感性的指标,并可能成为治疗化疗耐药卵巢癌患者的新型治疗靶点。

关键词: 化学药物治疗耐药, 卵巢癌, 驱动蛋白家族成员2C

Abstract: Objective To investigate the relationship between kinesin family proteins 2C (KIF2C) and chemoresistance in ovarian cancer. Methods Totally 151 patients with epithelial ovarian cancer who underwent surgery in Beijing Tongren Hospital, Capital Medical University from January 2010 to December 2020 were selected. Among them, 98 patients were sensitive to platinum chemotherapy and 53 patients were resistant to platinum chemotherapy. The expression of KIF2C in chemosensitive and chemoresistant ovarian cancer was detected by immunohistochemistry. Results The expression of KIF2C was significantly lower in the chemoresistant tissues of ovarian cancer. KIF2C and pathological stage ⅢC are the risk factors of chemotherapy resistance in ovarian cancer. Conclusion KIF2C may become a marker for predicting the chemosensitivity of ovarian cancer patients and a new therapeutic target in resistant ovarian cancer.

Key words: chemotherapy resistance, ovarian cancer, kinesin family proteins 2C (KIF2C)

中图分类号:

R737.31

王文文, 蔡昱, 贾双双, 翟建军. 驱动蛋白家族成员2C与卵巢癌化学药物治疗耐药的相关性[J]. 首都医科大学学报, 2023, 44(1): 143-147.

Wang Wenwen, Cai Yu, Jia Shuangshuang, Zhai Jianjun. Relationship between kinesin family proteins 2C and chemoresistance in ovarian cancer[J]. Journal of Capital Medical University, 2023, 44(1): 143-147.

参考文献

[1] Siegel R L, Miller K D, Fuchs H E, et al. Cancer statistics,2022[J]. CA Cancer J Clin, 2022, 72(1): 7-33.
[2] Christie E L, Bowtell D D L. Acquired chemotherapy resistance in ovarian cancer[J]. Ann Oncol, 2017, 28(Suppl 8): viii13－viii15.
[3] Chandra A, Pius C, Nabeel M, et al. Ovarian cancer: current status and strategies for improving therapeutic outcomes[J]. Cancer Med, 2019, 8(16): 7018-7031.
[4] Wang W W, Zhang W W, Hu Y J. Identification of keygenes, miRNAs and miRNA-mRNA regulatory pathways for chemotherapy resistance in ovarian cancer[J]. PeerJ, 2021, 9: e12353.
[5] Gan H Z, Lin L, Hu N J, et al. KIF2C exerts an oncogenic role in nonsmall cell lung cancer and is negatively regulated by miR-325-3p[J]. Cell Biochem Funct, 2019, 37(6): 424-431.
[6] Bie L, Zhao G, Wang Y P, et al. Kinesin family member 2C (KIF2C/MCAK) is a novel marker for prognosis in human gliomas[J]. Clin Neurol Neurosurg, 2012, 114(4): 356-360.
[7] Wei S, Dai M M, Zhang C, et al. KIF2C: a novel link between Wnt/β-catenin and mTORC1 signaling in the pathogenesis of hepatocellular carcinoma[J]. Protein Cell, 2021, 12(10): 788-809.
[8] Gnjatic S, Cao Y R, Reichelt U, et al. NY-CO-58/KIF2C is overexpressed in a variety of solid tumors and induces frequent T cell responses in patients with colorectal cancer[J]. Int J Cancer, 2010, 127(2): 381-393.
[9] Armstrong D K, Alvarez R D, Bakkum-Gamez J N, et al. Ovarian cancer, version 2.2020, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2021, 19(2): 191-226.
[10] Johnston S R D. Ovarian cancer: review of the National Institute for Clinical Excellence (Nice) guidance recommendations[J]. Cancer Invest, 2004, 22(5): 730-742.
[11] Banks J D, Heald R. Chromosome movement: dynein-out at the kinetochore[J]. Curr Biol, 2001, 11(4): R128-R131.
[12] Kinoshita K, Noetzel T L, Arnal I, et al. Global and local control of microtubule destabilization promoted by a catastrophe kinesin MCAK/XKCM1[J]. J Muscle Res Cell Motil, 2006, 27(2): 107-114.
[13] Xia P, Zhou J H, Song X Y, et al. Aurora A orchestrates entosis by regulating a dynamic MCAK-TIP150 interaction[J]. J Mol Cell Biol, 2014, 6(3): 240-254.
[14] Bendre S, Rondelet A, Hall C, et al. GTSE1 tunes microtubule stability for chromosome alignment and segregation by inhibiting the microtubule depolymeraseMCAK[J]. J Cell Biol, 2016, 215(5): 631-647.
[15] Yang J, Wu Z M, Yang L, et al. Characterization of kinesin family member 2C as a proto-oncogene in cervical cancer[J]. Front Pharmacol, 2022, 12: 785981.
[16] An L F, Zhang J, Feng D L, et al. KIF2C is a novel prognostic biomarker and correlated with immune infiltration in endometrial cancer[J]. Stem Cells Int, 2021, 2021: 1434856.
[17] Sanhaji M, Friel C T, Wordeman L, et al. Mitotic centromere-associated kinesin (MCAK): a potential cancer drug target[J]. Oncotarget, 2011, 2(12): 935-947.
[18] Ganguly A, Yang H L, Cabral F. Overexpression of mitotic centromere-associated kinesin stimulates microtubule detachment and confers resistance to paclitaxel[J]. Mol Cancer Ther, 2011, 10(6): 929-937.
[19] Ganguly A, Yang H L, Pedroza M, et al. Mitotic centromere-associated kinesin (MCAK) mediates paclitaxel resistance[J]. J Biol Chem, 2011, 286(42): 36378-36384.
[20] Jiang C F, Xie Y X, Qian Y C, et al. TBX15/miR-152/KIF2C pathway regulates breast cancer doxorubicin resistance via promoting PKM2 ubiquitination[J]. Cancer Cell Int, 2021, 21(1): 542.

驱动蛋白家族成员2C与卵巢癌化学药物治疗耐药的相关性

Relationship between kinesin family proteins 2C and chemoresistance in ovarian cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 7

编辑推荐

Metrics

本文评价

[1]	刘群, 李丽娜, 刘健, 苗劲蔚. 卵巢癌SOX4介导TGF-β1诱导的上皮间质转化对侵袭转移能力的影响[J]. 首都医科大学学报, 2022, 43(3): 336-342.
[2]	张紫欣, 孟颖, 梁宇霆. 双模态对比剂Fe₃O₄-Cy5.5-NGR在卵巢癌的体外靶向效能研究[J]. 首都医科大学学报, 2018, 39(1): 84-91.
[3]	刘晨, 吴龙, 蒋宏传, 李杰, 刘军, 王淑珍. 乳腺癌术后并发妇科生殖道恶性肿瘤的高危因素分析[J]. 首都医科大学学报, 2017, 38(1): 92-96.
[4]	丁翔;李红霞. 卵巢癌组织中鸟氨酸脱羧酶基因过度扩增及其临床意义[J]. 首都医科大学学报, 2009, 30(3): 289-292.
[5]	李金凤;张震宇;王淑珍;刘晋玮. 卵巢癌细胞和脐血树突状细胞融合瘤苗的体外培养与免疫原性的研究[J]. 首都医科大学学报, 2007, 28(5): 604-608.
[6]	魏薇;沈铿;赵丽红;曹阳. Fischer344大鼠上皮性卵巢癌动物模型的建立[J]. 首都医科大学学报, 2007, 28(1): 52-55.
[7]	林宇庚;张震宇;王立生;吴彬. 野生型p53,GM-CSF和B7-1基因转移对卵巢癌细胞系SKOV-3增生的影响[J]. 首都医科大学学报, 2005, 26(5): 588-592.